Codexis, Inc. (NASDAQ:CDXS) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.11 per share.
For the full year, analysts predict revenues of $ 68.40 million, while looking forward to loss of $ 0.39 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 78.00 million ~ $ 82.00 million
Click Here For More Historical Outlooks Of Codexis, Inc.
Previous Quarter Performance
Codexis, Inc. outlined loss for the second quarter of $ 0.11 per share, from the revenue of $ 14.97 million. The quarterly revenues swell 21.51 percent compared with the same quarter last year. Wall street analysts are predicting, CDXS to report 2Q20 loss of $ 0.19 per share from revenue of $ 11.23 million. The bottom line results beat street analysts by $ 0.08 or 42.11 percent, at the same time, top line results outshined analysts by $ 3.74 million or 33.30 percent.
Stock Performance
Shares of Codexis, Inc. traded up $ 0.61 or 4.50 percent on Wednesday, reaching $ 14.17 with volume of 192.00 thousand shares. Codexis, Inc. has traded high as $ 14.25 and has cracked $ 13.45 on the downward trend
The closing price of $ 14.17, representing a 60.85 % increase from the 52 week low of $ 8.43 and a 28.14 % decrease over the 52 week high of $ 18.87.
The company has a market capital of $ 837.83 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Codexis, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.codexis.com
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening.
